Pasithea closes $5M public offering, receives $1.3M from warrant exercises

Pasithea Therapeutics Corp.

Offered 3,571,428 units at $1.40/unit (common stock or pre-funded warrant + Series C/D warrants); gross $5M.
Additional $1.3M from exercise of 914,286 Series D warrants at closing; total gross proceeds $6.3M.
Net proceeds ~$4.3M after fees and expenses; intended for R&D, clinical trials, and general corporate.
H.C. Wainwright acted as exclusive placement agent; 7% cash fee plus warrants for 250,000 shares at $1.75.
90-day lockup on further equity issuance; one-year restriction on variable rate transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.